(Q47438666)

16 January 2018

title

Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma (English)

1 reference

https://api.crossref.org/works/10.1016/S0009-9120(03)00102-4

22 March 2024

author name string

Randa Abdel-Wahab Reda Mabrouk

1

1 reference

16 January 2018

Randa Ali-Labib

2

1 reference

16 January 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14563447

22 March 2024

publication date

1 October 2003

1 reference

16 January 2018

full work available at URL

https://api.elsevier.com/content/article/PII:S0009912003001024?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0009-9120(03)00102-4

https://api.elsevier.com/content/article/PII:S0009912003001024?httpAccept=text/plain

22 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0009-9120(03)00102-4

22 March 2024

published in

Clinical Biochemistry

1 reference

16 January 2018

volume

36

1 reference

16 January 2018

issue

7

1 reference

16 January 2018

page(s)

537-543

1 reference

16 January 2018

Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

HER-2/neu signal transduction in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Detection of soluble urokinase receptor by immunoradiometric assay and its application in tumor patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Correlation of tissue and blood plasminogen activation system in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Detection of ErbB2 oversignalling in a majority of breast cancers with phosphorylation-state-specific antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Prognostic importance of low c-erbB2 expression in breast tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Serial serum c-erbB-2 levels in patients with breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

c-erbB2 gene amplification and protein expression in ovarian epithelial tumors: evaluation of their respective prognostic significance by multivariate analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

ErbB-2 protein in sera and tumors of breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

C-erbB-2 protein in the sera of breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Serum c-erbB-2 in breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Serum c-erB-2 levels in monitoring of operable breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Utility of c-erbB-2 expression in tissue and sera of ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2803%2900102-4

Tissue urokinase-type plasminogen activator receptor levels in breast cancer

7 January 2021

6

1 reference

https://api.crossref.org/works/10.1016/S0009-9120(03)00102-4

Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients

22 March 2024

13

1 reference

https://api.crossref.org/works/10.1016/S0009-9120(03)00102-4

Detection of p105 (c-erbB-2, HER2/neu) serum levels by a new ELISA in patients with ovarian carcinoma

22 March 2024

39

1 reference

https://api.crossref.org/works/10.1016/S0009-9120(03)00102-4

22 March 2024

Identifiers

1 reference

16 January 2018

1 reference

16 January 2018